$74 NEW N-TRON 108TX ETHERNET SWITCH 8-PORTS 10/30-VDC 250-MA Business Industrial Industrial Automation Motion C PLCs HMIs PLC Peripheral Modules PLC Ethernet Communication See more N-Tron 108TX Industrial NEW Ranking TOP18 N-TRON 108TX ETHERNET SWITCH 250-MA 10 30-VDC 8-PORTS Business Industrial , Industrial Automation Motion C , PLCs HMIs , PLC Peripheral Modules , PLC Ethernet Communication , See more N-Tron 108TX Industrial,NEW,$74,10/30-VDC,N-TRON,ETHERNET,/misidentification290955.html,108TX,250-MA,sparkemirates.ae,SWITCH,8-PORTS Business Industrial , Industrial Automation Motion C , PLCs HMIs , PLC Peripheral Modules , PLC Ethernet Communication , See more N-Tron 108TX Industrial,NEW,$74,10/30-VDC,N-TRON,ETHERNET,/misidentification290955.html,108TX,250-MA,sparkemirates.ae,SWITCH,8-PORTS $74 NEW N-TRON 108TX ETHERNET SWITCH 8-PORTS 10/30-VDC 250-MA Business Industrial Industrial Automation Motion C PLCs HMIs PLC Peripheral Modules PLC Ethernet Communication See more N-Tron 108TX Industrial NEW Ranking TOP18 N-TRON 108TX ETHERNET SWITCH 250-MA 10 30-VDC 8-PORTS

NEW Ranking TOP18 N-TRON 108TX New color ETHERNET SWITCH 250-MA 10 30-VDC 8-PORTS

NEW N-TRON 108TX ETHERNET SWITCH 8-PORTS 10/30-VDC 250-MA

$74

NEW N-TRON 108TX ETHERNET SWITCH 8-PORTS 10/30-VDC 250-MA

|||

Item specifics

Condition:
New – Open box:
An item in excellent, new condition with no functional defects. The item may be missing original packaging and may have been used for testing or demo purposes. The item includes accessories found with the original product and may include a warranty. See the seller's listing for full details and description.
Seller Notes:
“UNUSED, SEE ALL PICTURES FOR MORE DETAILS”
Model:
N-TRON 108TX
MPN:
108TX
Brand:
N-TRON
UPC:
Does not apply








NEW N-TRON 108TX ETHERNET SWITCH 8-PORTS 10/30-VDC 250-MA

Council for europe portal
Language : en Search
Choose language
European network of OMCLs News 11 January 2022 Strasbourg, France
The Active Pharmaceutical Ingredient (API) Working Group of the General European OMCL Network (GEON) has conducted two market surveillance studies on omeprazole and sildenafil, the results of which have been published in the Journal of Pharmaceutical and Biomedical Analysis, Vol. 208...
European Pharmacopoeia / Monograph News 10 January 2022 Strasbourg, France
This document is intended to help stakeholders understand the advantages of applying for a monograph elaboration via European Pharmacopoeia (Ph. Eur.) procedure 4. It describes how Group P4 has elaborated P4 monographs over the last 10 years. It also applies to monographs on...
European Pharmacopoeia / Public enquiry News 10 January 2022 Strasbourg, France
The European Pharmacopoeia (Ph. Eur.) is seeking stakeholder feedback on the revised general chapters Colony-forming cell assay for human haematopoietic progenitor cells (2.7.28) and Nucleated cell count and viability (2.7.29), published in this quarter’s issue of Pharmeuropa (34.1)...

More news

The European Directorate for the Quality of Medicines & HealthCare (EDQM) announces the availability of 3 new European Pharmacopoeia (Ph. Eur.) reference standards and 11 replacement batches for Ph. Eur. reference standards in...
To check whether orders for publications or reference standards can be shipped in 2021, users are invited to consult the EDQM order reception deadlines for December.
The harmonised general chapter Chromatography was signed-off by the Pharmacopoeial Discussion Group (PDG), which brings together the European Pharmacopoeia (Ph. Eur.), Japanese Pharmacopoeia (JP) and the United States Pharmacopeia (...

Agenda

Nitrosamine contamination
In brief

Since N-nitrosamines, possible carcinogens for humans, were detected in 2018 in a number of active substances, the EDQM has been working with regulatory authorities to ensure that no medicinal products containing nitrosamine contaminants reach the end user. This has involved, among others, reviewing Certificates of suitability (used in marketing authorisation applications), revising European Pharmacopoeia monographs for the active substances concerned and establishing new reference standards to support the implementation of the new Ph. Eur. general chapter on the analysis of N-nitrosamines. The EDQM OMCL Network has also co-ordinated the development of testing procedures that ensure adequate control of impurities and a risk-based sampling and testing programme.

The Vision of the EDQM
In brief
  • A Directorate of the Council of Europe created in 1964.
  • A leading organisation that protects public health by enabling the development, supporting the implementation and monitoring the application of quality standards for safe medicines and their safe use.
  • Also develops guidance and standards in the areas of blood transfusion, organ transplantation and consumer health issues.
The European Pharmacopoeia
In brief
  • Main objective is to provide common quality standards to control the quality of medicines and of substances used in the manufacture of medicines (human and veterinary use).
  • Legally binding in European member states.
  • 39 signatory parties (including the EU) and 30 observers (including WHO and TFDA) as of March 2018.
Official Medicines Control Laboratories (OMCL)
In brief
  • A network of independent public laboratories appointed by the national authorities.
  • Around 70 laboratories provide human and technical resources to implement testing programmes.
  • 36 European countries and 5 countries outside Europe participate in the various activities and programmes.
The Certification of Suitability
In brief

 

  • Established in 1994.
  • Over 4,900 certificates covering more than 1,100 substances have been granted in more than 60 countries.
  • Assessment is jointly performed by a network of around 100 assessors from the national competent authorities and EDQM assessors.
  • Organises an inspection programme involving a network of around 30 inspectors from 20 different national competent authorities and the EDQM.

 

1
2
3
4
5
COVID-19 pandemic
Focus

 

The EDQM’s core activities include the provision of documentary and physical (reference) standards to ensure the quality of medicines and their ingredients. Availability of and access for patients to quality medicines is more important than ever in the context of the current COVID-19 pandemic. This is why the EDQM is working hard to ensure the continuous supply of our goods and services and is engaging with all stakeholders, including national, European and international authorities, to help protect public health.

 

 

Latest products and services

How to order

Via our web store at store.edqm.eu in order to benefit from free handling charges (on publications only). Alternatively, you can send your order to the EDQM Sales section by:

  • post: EDQM – Council of Europe, 7 allée Kastner, CS 30026, 67081 Strasbourg, France
  • e-mail: orders@edqm.eu

Invoices can be paid by credit card via internet or by bank transfer.

@Edqm_news on Twitter

Videos